Eyepoint Retained Earnings from 2010 to 2025

EYPT Stock

USD 7.17 0.48 6.27%

Eyepoint Pharmaceuticals Retained Earnings yearly trend continues to be comparatively stable with very little volatility. Retained Earnings are likely to outpace its year average in 2025. Retained Earnings is the cumulative amount of net income that Eyepoint Pharmaceuticals retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. View All Fundamentals

Retained Earnings

First Reported

2003-06-30

Previous Quarter

-802.3 M

Current Value

-831.6 M

Quarterly Volatility

196.8 M

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Eyepoint Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eyepoint Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 396.7 K, Interest Expense of 1.6 M or Total Revenue of 55.6 M, as well as many indicators such as Price To Sales Ratio of 20.8, Dividend Yield of 0.0 or PTB Ratio of 3.59. Eyepoint financial statements analysis is a perfect complement when working with Eyepoint Pharmaceuticals Valuation or Volatility modules.

Check out the analysis of Eyepoint Pharmaceuticals Correlation against competitors.

For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.

Latest Eyepoint Pharmaceuticals' Retained Earnings Growth Pattern

Below is the plot of the Retained Earnings of Eyepoint Pharmaceuticals over the last few years. It is the cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends. Eyepoint Pharmaceuticals' Retained Earnings historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eyepoint Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (742.15 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Retained Earnings

Timeline

Eyepoint Retained Earnings Regression Statistics

	Arithmetic Mean	(407,523,500)
	Geometric Mean	289,693,097
	Coefficient Of Variation	(50.81)
	Mean Deviation	176,045,216
	Median	(310,820,000)
	Standard Deviation	207,057,154
	Sample Variance	42872.7T
	Range	739.8M
	R-Value	(0.95)
	Mean Square Error	4472.5T
	R-Squared	0.90
	Slope	(41,319,218)
	Total Sum of Squares	643090T

Eyepoint Retained Earnings History

	2025	-634.5 M
	2024	-667.9 M
	2023	-742.1 M
	2022	-671.4 M
	2021	-569.1 M
	2020	-510.7 M
	2019	-465.3 M

Other Fundumenentals of Eyepoint Pharmaceuticals

Retained Earnings Total Equity

Eyepoint Pharmaceuticals Retained Earnings component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Net Receivables	Total Liab	Total Current Assets	Intangible Assets	Common Stock	Accounts Payable	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Short Term Debt	Short Term Investments	Net Tangible Assets	Capital Surpluse	Deferred Long Term Liab	Net Invested Capital	Net Working Capital	Long Term Debt Total	Short Long Term Debt	Capital Stock
Total Assets		0.99	-0.96	-0.85	0.18	0.88	1.0	0.51	-0.18	0.66	0.81	-0.2	0.65	-0.23	0.92	0.85	0.79	0.4	1.0	1.0	0.58	-0.73	-0.76
Total Stockholder Equity	0.99		-0.98	-0.77	0.07	0.79	0.99	0.38	-0.29	0.55	0.78	-0.16	0.54	-0.19	0.93	0.86	0.72	0.3	0.98	0.99	0.47	-0.61	-0.69
Net Debt	-0.96	-0.98		0.74	0.02	-0.73	-0.96	-0.34	0.36	-0.48	-0.74	0.15	-0.46	0.17	-0.89	-0.82	-0.71	-0.28	-0.95	-0.96	-0.38	0.57	0.65
Retained Earnings	-0.85	-0.77	0.74		-0.46	-0.92	-0.83	-0.65	-0.19	-0.77	-0.78	0.51	-0.8	0.53	-0.79	-0.71	-0.89	-0.62	-0.84	-0.82	-0.71	0.85	0.82
Net Receivables	0.18	0.07	0.02	-0.46		0.46	0.14	0.51	0.83	0.54	0.61	-0.17	0.63	-0.17	0.18	0.39	0.53	0.43	0.21	0.17	0.68	-0.55	-0.55
Total Liab	0.88	0.79	-0.73	-0.92	0.46		0.85	0.78	0.15	0.88	0.77	-0.28	0.88	-0.3	0.75	0.7	0.86	0.62	0.87	0.85	0.79	-0.96	-0.84
Total Current Assets	1.0	0.99	-0.96	-0.83	0.14	0.85		0.45	-0.22	0.62	0.8	-0.19	0.61	-0.21	0.94	0.86	0.78	0.37	0.99	1.0	0.54	-0.69	-0.75
Intangible Assets	0.51	0.38	-0.34	-0.65	0.51	0.78	0.45		0.35	0.81	0.49	-0.27	0.75	-0.29	0.34	0.35	0.62	0.58	0.49	0.44	0.68	-0.87	-0.55
Common Stock	-0.18	-0.29	0.36	-0.19	0.83	0.15	-0.22	0.35		0.26	0.28	-0.31	0.32	-0.3	-0.13	0.06	0.25	0.34	-0.16	-0.2	0.32	-0.28	-0.26
Accounts Payable	0.66	0.55	-0.48	-0.77	0.54	0.88	0.62	0.81	0.26		0.59	-0.25	0.92	-0.27	0.48	0.47	0.72	0.66	0.67	0.62	0.88	-0.93	-0.56
Property Plant Equipment	0.81	0.78	-0.74	-0.78	0.61	0.77	0.8	0.49	0.28	0.59		-0.17	0.64	-0.19	0.79	0.95	0.83	0.41	0.83	0.82	0.58	-0.68	-0.83
Current Deferred Revenue	-0.2	-0.16	0.15	0.51	-0.17	-0.28	-0.19	-0.27	-0.31	-0.25	-0.17		-0.22	1.0	-0.18	-0.13	-0.24	-0.29	-0.17	-0.16	-0.2	0.25	0.19
Long Term Debt	0.65	0.54	-0.46	-0.8	0.63	0.88	0.61	0.75	0.32	0.92	0.64	-0.22		-0.24	0.46	0.45	0.76	0.79	0.67	0.62	0.94	-0.91	-0.72
Short Term Debt	-0.23	-0.19	0.17	0.53	-0.17	-0.3	-0.21	-0.29	-0.3	-0.27	-0.19	1.0	-0.24		-0.2	-0.15	-0.26	-0.3	-0.2	-0.18	-0.22	0.27	0.2
Short Term Investments	0.92	0.93	-0.89	-0.79	0.18	0.75	0.94	0.34	-0.13	0.48	0.79	-0.18	0.46	-0.2		0.88	0.74	0.21	0.91	0.93	0.4	-0.57	-0.71
Net Tangible Assets	0.85	0.86	-0.82	-0.71	0.39	0.7	0.86	0.35	0.06	0.47	0.95	-0.13	0.45	-0.15	0.88		0.76	0.22	0.87	0.87	0.4	-0.57	-0.73
Capital Surpluse	0.79	0.72	-0.71	-0.89	0.53	0.86	0.78	0.62	0.25	0.72	0.83	-0.24	0.76	-0.26	0.74	0.76		0.65	0.8	0.78	0.65	-0.85	-0.81
Deferred Long Term Liab	0.4	0.3	-0.28	-0.62	0.43	0.62	0.37	0.58	0.34	0.66	0.41	-0.29	0.79	-0.3	0.21	0.22	0.65		0.44	0.38	0.58	-0.71	-0.49
Net Invested Capital	1.0	0.98	-0.95	-0.84	0.21	0.87	0.99	0.49	-0.16	0.67	0.83	-0.17	0.67	-0.2	0.91	0.87	0.8	0.44		1.0	0.58	-0.73	-0.76
Net Working Capital	1.0	0.99	-0.96	-0.82	0.17	0.85	1.0	0.44	-0.2	0.62	0.82	-0.16	0.62	-0.18	0.93	0.87	0.78	0.38	1.0		0.54	-0.69	-0.75
Long Term Debt Total	0.58	0.47	-0.38	-0.71	0.68	0.79	0.54	0.68	0.32	0.88	0.58	-0.2	0.94	-0.22	0.4	0.4	0.65	0.58	0.58	0.54		-0.81	-0.67
Short Long Term Debt	-0.73	-0.61	0.57	0.85	-0.55	-0.96	-0.69	-0.87	-0.28	-0.93	-0.68	0.25	-0.91	0.27	-0.57	-0.57	-0.85	-0.71	-0.73	-0.69	-0.81		0.76
Capital Stock	-0.76	-0.69	0.65	0.82	-0.55	-0.84	-0.75	-0.55	-0.26	-0.56	-0.83	0.19	-0.72	0.2	-0.71	-0.73	-0.81	-0.49	-0.76	-0.75	-0.67	0.76

Click cells to compare fundamentals

About Eyepoint Pharmaceuticals Financial Statements

Eyepoint Pharmaceuticals shareholders use historical fundamental indicators, such as Retained Earnings, to determine how well the company is positioned to perform in the future. Although Eyepoint Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Eyepoint Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Eyepoint Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Retained Earnings	-667.9 M	-634.5 M
Retained Earnings Total Equity	-604.2 M	-634.4 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Eyepoint Stock Analysis

When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC